CStone directors and executives acquire 2.42 million shares; company cancels 4.60 million buy-backs as CS2009 advances toward global Phase III

Bulletin Express

Jul 23

CStone Pharmaceuticals disclosed that Chief Executive Officer Dr. Jianxin Yang, fellow directors and senior management bought 2.42 million shares on the open market in June 2026 under their Joint Share Purchase Plan. Dr. Yang accounted for 1.24 million shares of the total.

Since taking the helm in August 2022, Dr. Yang has accumulated 13.71 million shares, lifting his stake to approximately 5.26 % of the company’s issued share capital.

Separately, CStone repurchased 4.60 million shares in June 2026 for cancellation, underscoring its stated commitment to shareholder returns and capital-structure optimisation.

Management linked the transactions to confidence in the company’s research pipeline and commercial rollout. Key asset CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, is in a global multi-centre Phase II study with interim results slated for release in the 2026 interim report and at the European Society for Medical Oncology Congress. The company intends to discuss Phase III multiregional clinical trial design with the U.S. FDA and aims to launch first-wave global Phase III trials by year-end.

CStone confirmed that, after the insider purchases and share cancellations, its public float remains in line with Hong Kong listing requirements and that all transactions complied with applicable regulations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1104837887"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1104837887\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1104837887?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-23 07:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104837887","market":"us","top_or_hot":-1,"title":"CStone directors and executives acquire 2.42 million shares; company cancels 4.60 million buy-backs as CS2009 advances toward global Phase III","media":"Bulletin Express","content":"<p>CStone Pharmaceuticals disclosed that Chief Executive Officer Dr. Jianxin Yang, fellow directors and senior management bought 2.42 million shares on the open market in June 2026 under their Joint Share Purchase Plan. Dr. Yang accounted for 1.24 million shares of the total.</p>\n<p>Since taking the helm in August 2022, Dr. Yang has accumulated 13.71 million shares, lifting his stake to approximately 5.26 % of the company’s issued share capital.</p>\n<p>Separately, CStone repurchased 4.60 million shares in June 2026 for cancellation, underscoring its stated commitment to shareholder returns and capital-structure optimisation.</p>\n<p>Management linked the transactions to confidence in the company’s research pipeline and commercial rollout. Key asset CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, is in a global multi-centre Phase II study with interim results slated for release in the 2026 interim report and at the European Society for Medical Oncology Congress. The company intends to discuss Phase III multiregional clinical trial design with the U.S. FDA and aims to launch first-wave global Phase III trials by year-end.</p>\n<p>CStone confirmed that, after the insider purchases and share cancellations, its public float remains in line with Hong Kong listing requirements and that all transactions complied with applicable regulations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CStone directors and executives acquire 2.42 million shares; company cancels 4.60 million buy-backs as CS2009 advances toward global Phase III</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCStone directors and executives acquire 2.42 million shares; company cancels 4.60 million buy-backs as CS2009 advances toward global Phase III\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-23 07:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CStone Pharmaceuticals disclosed that Chief Executive Officer Dr. Jianxin Yang, fellow directors and senior management bought 2.42 million shares on the open market in June 2026 under their Joint Share Purchase Plan. Dr. Yang accounted for 1.24 million shares of the total.</p>\n<p>Since taking the helm in August 2022, Dr. Yang has accumulated 13.71 million shares, lifting his stake to approximately 5.26 % of the company’s issued share capital.</p>\n<p>Separately, CStone repurchased 4.60 million shares in June 2026 for cancellation, underscoring its stated commitment to shareholder returns and capital-structure optimisation.</p>\n<p>Management linked the transactions to confidence in the company’s research pipeline and commercial rollout. Key asset CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, is in a global multi-centre Phase II study with interim results slated for release in the 2026 interim report and at the European Society for Medical Oncology Congress. The company intends to discuss Phase III multiregional clinical trial design with the U.S. FDA and aims to launch first-wave global Phase III trials by year-end.</p>\n<p>CStone confirmed that, after the insider purchases and share cancellations, its public float remains in line with Hong Kong listing requirements and that all transactions complied with applicable regulations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02616","symbol_name":"基石药业-B","start_time":0,"source_url":"","article_id":"1104837887","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104837887","pubTimestamp":1784761366,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CStone Pharmaceuticals disclosed that Chief Executive Officer Dr. Jianxin Yang, fellow directors and senior management bought 2.42 million shares on the open market in June 2026 under their Joint...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02616":"基石药业-B"},"translate_title":"基石董事和高管收购242万股股票；随着 CS2009 全球第三阶段的推进，公司取消了 460 万笔回购","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02616":1},"content_text":"CStone Pharmaceuticals disclosed that Chief Executive Officer Dr. Jianxin Yang, fellow directors and senior management bought 2.42 million shares on the open market in June 2026 under their Joint Share Purchase Plan. Dr. Yang accounted for 1.24 million shares of the total.\nSince taking the helm in August 2022, Dr. Yang has accumulated 13.71 million shares, lifting his stake to approximately 5.26 % of the company’s issued share capital.\nSeparately, CStone repurchased 4.60 million shares in June 2026 for cancellation, underscoring its stated commitment to shareholder returns and capital-structure optimisation.\nManagement linked the transactions to confidence in the company’s research pipeline and commercial rollout. Key asset CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, is in a global multi-centre Phase II study with interim results slated for release in the 2026 interim report and at the European Society for Medical Oncology Congress. The company intends to discuss Phase III multiregional clinical trial design with the U.S. FDA and aims to launch first-wave global Phase III trials by year-end.\nCStone confirmed that, after the insider purchases and share cancellations, its public float remains in line with Hong Kong listing requirements and that all transactions complied with applicable regulations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,merge,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}